17 matches for your search in the start-up spotlight
rss
Seed funding to accelerate the development of a pipeline for targeted protein degradation
12-Mar-2025
TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, announced the closing of its $31 million (£25 million) seed funding round. The financing was led by Cambridge Innovation Capital (CIC) and SV Health Investors’ ...
Funding will accelerate the company's anti-amyloid treatment for rare and common forms of dementia
27-Jan-2025
Icelandic drug discovery and development company Arctic Therapeutics (ATx) announced the successful closing of a €26.5 million oversubscribed Series A financing from a broad syndicate of international investors. The syndicate includes the EIC Fund, Iceland's largest privately-held investment firm ...
Activating the Memory System of the Brain with Software to Treat Alzheimer’s Disease
04-Nov-2024
Nuuron is developing a fully digital Alzheimer’s therapy based on a proprietary neuromodulation technology. Nuuron’s algorithms produce ultra-high frequency, digital-photonic stimuli that activate the Memory System of Alzheimer’s patients, aiming to improve memory formation and memory recall. ...
There is a huge market for the treatment of patients with degenerative brain diseases
15-Apr-2024
The Basel spin-off company Bottneuro is developing a personalized treatment helmet – the Miamind neurostimulator. Thanks to targeted brain electrostimulation, the innovative device is intended to have a positive effect on the course of diseases such as Alzheimer’s, as there is a huge market for ...
German-US research team and Magdeburg-based start-up have proven that memory problems can be recognised using an app
05-Apr-2024
Dedicated memory tests on smartphones enable the detection of “mild cognitive impairment”, a condition that may indicate Alzheimer’s disease, with high accuracy. Researchers from DZNE, the Otto-von-Guericke University Magdeburg and the University of Wisconsin-Madison in the United States who ...
New collaboration will enhance ability to identify those more at risk of developing brain diseases to enable earlier interventions
04-Mar-2024
PharmaKure announces a new epigenetics collaboration with Sheffield Hallam University. This partnership will focus on ‘gene-based environmental biomarkers’, known as epigenetic markers, for calculating risk scores for Alzheimer’s diseases. Together withALZmetrixTM, PharmaKure’s blood-based ...
Grants to advance innovative drug programs for age-related diseases of the CNS and muscle
14-Feb-2024
Vandria SA announced that it has been awarded two grants totalling € 3.8M from Innosuisse and Eurostars to support its two lead drug candidates addressing CNS and muscle diseases, respectively. This financial support from two independent research granting agencies is validation of Vandria’s ...
27-Nov-2023
The Alzheimer’s drug candidate PRI-002 is entering the next clinical trial phase: the European Medicines Agency (EMA) has granted approval to conduct a phase II clinical trial. This is the first time that the drug candidate will be tested on a larger number of Alzheimer’s patients. The drug was ...
Biotech start-up company developing new treatments for neurodegenerative conditions based on amplifying the brain's own physiological protective mechanisms
16-Oct-2023
AstronauTx Ltd., a biotech company developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, announced the completion of a £48 million ($61 million) Series A financing. The financing was led by the Novartis Venture Fund attracting capital from several leading ...
New platform has potential to fuel advances in senolytic anti-aging compounds and longevity research
09-May-2023
Anew publicationin the May issue ofNature Agingby researchers from Integrated Biosciences, a biotechnology start-up company combining synthetic biology and machine learning to target aging, demonstrates the power of artificial intelligence (AI) to discover novel senolytic compounds, a class ...
